The state of hemostasis in patients with CKD VD stage with some comorbid conditions


Keywords: сhronic kidney disease, hemodialysis, hemostasis, comorbidity.

Abstract

Annotation. Clinical observations indicate that one of the rather important mechanisms in the pathogenesis of complications in CKD stage VD are disorders in the hemostatic system leading to the development of thrombophilia. Comorbidity in this category of patients significantly worsens the prognosis due to the potentiation of hypercoagulation, which, as a comorbid syndrome, accelerates morphological changes in the kidneys, contributes to the deposition of fibrin in the glomeruli and the development of thrombosis. The aim of the study was to study the indices of the main links of hemostasis depending on some comorbid conditions (acute inflammation, secondary hyperparathyroidism, hepatitis B and C). The study involved 52 men and 36 women with CKD stage VD, who were on programmed hemodialysis, in whom the levels of soluble fibrin, D-dimer, fibrinogen, protein C, indicators of hemostatic potential in these comorbid conditions were determined. Statistical processing of materials was performed using the methods of variation statistics.It was determined that the presence of a fast phase of inflammation enhances the processes of hypercoagulability, and a high level of parathyroid hormone (˃800 pg/ml) in combination with hyperphosphoremia slightly increases the level of fibrinogen. Infection with hepatitis C significantly increases the level of soluble fibrin, and infection with hepatitis B decreases the level of protein C. The study and implementation of a comprehensive assessment of the state of hemostasis in patients with CKD stage VD complicated by comorbid diseases makes it possible to identify imbalances in the pro- and anticoagulation system.

References

1. Volkov, G. L., Platonova, T. N., Savchuk, A. M., Gornitskaya, O. V., Chernyshenko, T. M., & Krasnobryzha, Ye. M. (2005). Sovremennyye predstavleniya o sisteme gemostaza [Modern concepts of the hemostasis system]. Kiyev: Naukova dumka. ISBN 966-00-0447-8.

2. Hutsalenko, O. O., Kostrikova, Y. A., Salo, L. M., Manoylo, O. V., & Falʹko, V. P. (2010). Polimorbidnistʹ yak mizhdystsyplinarna problema [Polymorbidity as an interdisciplinary problem]. Svit medytsyny ta biolohiyi – The world of medicine and biology, 2, 10–13. Vziato z https://cyberleninka.ru/article/n/polimorbidnist-yak-mizhdistsiplinarna-problema/viewer.

3. Dudar, I. O., Driianska, V. Ye., Savchuk, V. M., Loboda, O. M., Honchar, Yu. I., Shifris, I. M., … & Krasiuk, E. K. (2017). Khronichne zapalennia ta anemiia u khvorykh na KhKhN VD stadia [Chronic inflammation and anemia in patients with CKD VD stage]. Ukr. zhurnal nefrolohii ta dializu – Ukr. Journal of Nephrology and Dialysis, 3 (55), 84–85.

4. Lesovoj, V. N., Andoneva, N. M., & Volkovskaya, T. L. (2017). Vliyanie vtorichnogo giperparatireoza na kalcifikaciyu klapanov serdca u bolnyh s hronicheskoj boleznyu pochek VD stadia [Effect of secondary hyperparathyroidism on heart valve calcification in patients with stage VD chronic kidney disease]. Ukr. zhurnal nefrolohii ta dializu – Ukr. Journal of Nephrology and Dialysis, 3 (55), 76–80.

5. Lesovoj, V. N., Andoneva, N. M., Guc, E. A., Dubovik, M. Ya., Grushka, M. A., & Lesovaya, G. V. (2013). Sindrom komorbidnosti u pacientov na pochechnozamestitelnoj terapii [Comorbidity syndrome in patients on renal replacement therapy] (s. 135–137). V Urolohiia, androlohiia, nefrolohiia, Materialy naukovo-praktychnoi konferentsii z mizhnarodnoiu uchastiu [In Urology, Andrology, Nephrology, Materials of the scientific-practical conference with international participation.]. Kharkiv.

6. Lugovskoj, E. V., Gricenko, P. G., Kolesnikova, I. N., Lugovskaya, N. E., Litvinova, L. M., Kostyuchenko, E. P., … & Komisarenko, S. V. (2009). Rastvorimyj fibrin i D-dimer kak molekulyarnye markery sosudistyh oslozhnenij u bolnyh saharnym diabetom [Soluble fibrin and D-dimer as molecular markers of vascular complications in patients with diabetes mellitus]. Dopovidi Natsionalnoi akademii nauk Ukrainy – Reports of the National Academy of Sciences of Ukraine, 12, 190–193. Vziato z http://dspace.nbuv.gov.ua/handle/123456789/19161.

7. Martyniuk, L. P., Ruzhytska, O. O., Vons, L. Z., Kozii, M. I., & Yakubyshyna, I. H. (2016). Funktsionalnyi stan pry shchytopodibnykh zaloz u khvorykh na khronichnu khvorobu nyrok v umovakh likuvannia hemodializom [Functional condition of the thyroid gland in patients with chronic kidney disease in hemodialysis]. Zdobutky klinichnoi i eksperymentalnoi medytsyny – Achievements of clinical and experimental medicine, 2, 125. Vziato z http://nbuv.gov.ua/UJRN/Zkem_2016_2_49.

8. Melnik, A. A. (2016). Sistema gemostaza i ee regulyaciya pri narushenii funkcionalnoj sposobnosti pochek [The hemostatic system and its regulation in violation of the functional ability of the kidneys]. Novosti mediciny i farmacii v Ukraine – News of medicine and pharmacy in Ukraine, 9 (583), 24–31. Vzyato s http://nbuv.gov.ua/UJRN/nirku_2016_3_10.

9. Паламар, Б. І., Красюк, Е. К., & Шилова, А. Ю. (2015). Гепатити у хворих, які лікуються гемодіалізом. Укр. журнал нефрології та діалізу, 5 (49), 4–16.

10. Platonova, T. M., Hornytska, O. V., & Moroz, E. O. (2004). Zastosuvannia aktyvatoru proteinu S z otruty shchytomordnyka zvychainoho (Agkistrodon halys halys) dlia vyznachennia aktyvnosti proteinu S u plazmi krovi za riznykh patolohii [The use of protein C activator from the venom of the common thyroid gland (Agkistrodon halys halys) to determine the activity of protein C in blood plasma in various pathologies]. Laboratorna diahnostyka – Laboratory diagnostics, 3, 28–31.

11. Rublenko, A. M., Urvant, L. P., Makohonenko, Ye. M., Platonova, T. M., Tsap, P. Yu., Chernyshenko, T. M., ... & Luhovskoi, E. V. (2011). Vplyv aktyvatora proteinu S na zahalnyi hemostatychnyi potentsial plazmy krovi za endoprotezuvannia tazostehnovoho suhloba [Influence of protein C activator on the total hemostatic potential of blood plasma during hip arthroplasty]. Ukr. biokhim. Zhurnal – Ukr. biochemistry magazine, 5 (83), 32–38. Vziato z http://docplayer.net/54728538-Vpliv-aktivatora-proteyinu-s-na-zagalniy-gemostatichniy-potencial-plazmi-krovi-za-endoprotezuvannya-tazostegnovogo-sugloba.html.

12. Cokolovsʹka, A. S., Platonova, T. M., Hrynenko, T. V., Chernyshenko, T. M., & Ivashchenko, T. I. (2002). Porivnialna kharakterystyka metodiv vyznachennia vmistu fibrynohenu v plazmi krovi [Comparative characteristics of methods for determining the content of fibrinogen in blood plasma]. Eksperym. ta klin. fiziol. i biokhimiia – Experimental and clinical physiology and biochemistry, 3, 82–86.

13. Suvorova, T. S., Tov, N. L., & Movchan, E. A. (2007). Sostoyanie sosudisto-trombocitarnogo i koagulyacionnogo zvenev gemostaza pri hronicheskom tubulointersticialnom nefrite [The state of the vascular-platelet and coagulation links of hemostasis in chronic tubulointerstitial nephritis]. Terapevt. arhiv – Therapeutic archive, 79 (6), 56–60.

14. Hil, M. Yu., Shejman, B. S., & Dudar, I. A. (2012). Osobennosti endotoksemii u bolnyh HBP VD, inficirovannyh hronicheskim gepatitom С [Features of endotoxemia in CKD VD patients infected with chronic hepatitis C]. V Aktualni pytannia nefrolohii, Materialy naukovo-praktychnoi konferentsii [In Topical issues of nephrology, Proceedings of the scientific-practical conference]. Ukr. zhurnal nefrolohii ta dializu – Ukr. Journal of Nephrology and Dialysis, 1 (33) (dodatok 1), 92–93.

15. Shyfris, I. M., & Dudar, I. O. (2015). Komorbidnist ta vyzhyvannia khvorykh na khronichnu khvorobu nyrok V D stadii [Comorbidity and survival of patients with chronic kidney disease stage V D]. Ukr. zhurnal nefrolohii ta dializu – Ukr. Journal of Nephrology and Dialysis, 4 (48), 30–39. Vziato z 2015-12-09_Nefrologia_block_№4 (48)-2015.indd.

16. Jiannong, L. (2010). An improved comorbidity index for outcome analyses among dialysis patients. Kidney international, 77 (2), 141–151. doi: 10.1038/ki.2009.413.

17. Korevaar, J. C., Von Manen, J. G., Dekker, F. W., de Waart, D. R., Boeschoten, E. W., & Krediet, R. T. (2004). Effect of an increase in C-reactive protein level during a haemodialysis session on mortality. J. Am. Soc. Nephrol., 15 (11), 2916–2922. doi: 10.1097/01.ASN.0000143744.72664.66.

18. Mosesson, M. W. (2005). Fibrinogen and fibrin structure and functions. J. Thromb. Haemost., 3 (8), 1894–904. doi: 10.1111/j.1538-7836.2005.01365.x.

19. Nunns, G. R., Moore, E. E., Chapman, M. P., Moore, H. B., Stettler, G. R., Peltz, E., (2017). The hypercoagulability paradox of chronic kidney disease: The role of fibrinogen. Am. J. Surg., 214 (6), 1215–1218. doi: 10.1016/j.amjsurg.2017.08.039.

20. Rattanasompattikul, M. (2012). Charlson comorbidity score is a strong predictor of mortality in haemodialysis patients. Int. Urol. Nephrol., 44 (6), 1813–23. doi: 10.1007/s11255-011-0085-9.

21. Storozhuk, B. G., Pyrogova, L. V., Chernyshenko, T. M., Kostiuchenko, T. M., Kolesnikova, I. M., Platonova, T. M., … & Lugovskoy, E. V. (2018). Overall Haemostasis potential of the blood plasma and its relation to some molecular markers of the haemostasis system in patients with chronic renal disease of stage VD. Ukr. Biochem. J., 90 (5), 61–71. doi: https://doi.org/10.15407/ubj90.05.060.

22. Storozhuk, O. B., Seleznyova, I. B., Storozhuk, L. O., Dovgalyuk, T. V., Storozhuk, B. G., & Platonova, T. N. (2020). Status of pro- and anticoagulant components of hemostasis in patients with stage VD CKD depending of residual renal function. Wiadomosci Lekarskie, 73 (8), 1723–1725. Doi:10.740WLek202008125.

23. Toh, C. H., & Dennis, M. (2003). Disseminated intravascular coagulation: old disease new hope. BMJ, 327 (7421), 974–977. doi: 10.1136/bmj.327.7421.974.
Published
2020-10-12
How to Cite
Postovitenko, K. P., Storozhuk, L. O., Seleznyova, I. B., Storozhuk, B. G., & Dovgalyuk, T. V. (2020). The state of hemostasis in patients with CKD VD stage with some comorbid conditions. Reports of Vinnytsia National Medical University, 24(2), 253-260. https://doi.org/https://doi.org/10.31393/reports-vnmedical-2020-24(2)-10